A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

Must have received: anti-CD20 monoclonal antibody-based immunotherapy or chemoimmunotherapy

Received 1 to 5 prior lines of systemic therapy including an anti-CD20 monoclonal antibody (mAb)-based immunotherapy or chemoimmunotherapy

Cannot have received: BCL2 inhibitor

Prior therapy with B-cell lymphoma-2 inhibitor (BCL2i)

Cannot have received: BTK degrader

Prior therapy with BTK degraders

Cannot have received: Bruton tyrosine kinase inhibitor

Exception: unless the participant was intolerant of non-zanubrutinib covalent or non-covalent BTKi

Prior therapy with covalent or non-covalent Bruton tyrosine kinase inhibitor (BTKi) unless the participant was intolerant of non-zanubrutinib covalent or non-covalent BTKi. Participants with refractory disease to BTKi therapy or relapse attributed to failure of BTKi therapy are ineligible.

Cannot have received: autologous stem cell transplantation

Prior autologous stem cell transplantation or chimeric antigen receptor T-cell therapy within 3 months before first dose of study drug

Cannot have received: chimeric antigen receptor T-cell therapy

Prior autologous stem cell transplantation or chimeric antigen receptor T-cell therapy within 3 months before first dose of study drug

Cannot have received: allogeneic stem cell transplant

Prior allogeneic stem cell transplant within 6 months of the first dose of the study drug